Covid-19 roundup: UAE claims Sinopharm vac­cine 86% ef­fec­tive, but de­tails are scant; In­dia re­port­ed­ly re­jects As­traZeneca's vac­cine, while UK con­ducts 'all en­com­pass­ing' re­view 

Over the past month we’ve learned, from Phase III tri­als, how well mR­NA and ade­n­ovirus-based vac­cines pro­tect peo­ple from Covid-19. And now, the first an­nounce­ment around an in­ac­ti­vat­ed jab sug­gests an ef­fi­ca­cy of 86%.

The can­di­date is de­vel­oped by the Bei­jing In­sti­tute of Bi­o­log­i­cal Prod­ucts, a sub­sidiary of Chi­na’s state-owned Sinopharm. On Wednes­day, the Unit­ed Arab Emi­rates’ Min­istry of Health and Pre­ven­tion an­nounced that they’ve reg­is­tered the vac­cine af­ter con­duct­ing a Phase III lo­cal­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER